Corticosteroid-induced osteoporosis

Area of Science:

• Endocrinology
• Rheumatology
• Osteoporosis Research

Background:

• Corticosteroids are widely used for various inflammatory and autoimmune conditions.
• Long-term corticosteroid use is associated with significant bone loss and increased fracture risk.
• Osteoporosis is a common complication, affecting 30-50% of patients on long-term therapy.

Purpose of the Study:

• To review the established link between corticosteroid use and bone loss.
• To highlight the efficacy of current treatments in preventing and managing corticosteroid-induced osteoporosis.
• To emphasize the importance of clinical awareness regarding fracture risk, especially in postmenopausal women.

Main Methods:

• Review of historical observations and clinical acceptance of corticosteroid-induced bone loss.
• Summary of randomized controlled trials demonstrating the effectiveness of osteoporosis treatments.
• Emphasis on clinical implications and risk stratification.

Main Results:

• Supraphysiologic corticosteroid doses are a primary cause of clinically significant bone loss.
• Fractures, particularly at the spine and hip, are common in patients on long-term corticosteroids.
• Effective treatments are available that preserve or increase bone mass and reduce fracture risk.

Conclusions:

• Corticosteroid-induced osteoporosis is a preventable condition.
• Appropriate drug treatments can significantly mitigate bone loss and fracture risk.
• Clinicians must recognize the high risk of vertebral fractures, especially in postmenopausal women using corticosteroids.